Parkinson disease (PD) is the second most common neurodegenerative disorder, affecting>
1% of the population≥ 65 years of age and with a prevalence set to double by 2030. In …

A hallmark event in neurodegenerative diseases (NDs) is the misfolding, aggregation, and
accumulation of proteins, leading to cellular dysfunction, loss of synaptic connections, and …

Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD).
In recent years, research has focused on the pre-dementia stages of cognitive impairment in …

In this review, the clinical features of Parkinson's disease, both motor and non‐motor, are
described in the context of the progression of the disease. Also briefly discussed are the …

Many risk loci for Parkinson's disease (PD) have been identified by genome-wide
association studies (GWASs), but target genes and mechanisms remain largely unknown …

Background Great heterogeneity exists in survival and the interval between onset of motor
symptoms and dementia symptoms across synucleinopathies. We aimed to identify genetic …

Non-motor symptoms (NMS) of Parkinson's disease can be predominant as the disease
advances, thereby constituting a major source of disease burden for patients and caregivers …

Background Parkinson's disease is associated with an increased incidence of cognitive
impairment and dementia. Predicting who is at risk of cognitive decline early in the disease …

Background Neurofilament light chain protein (NfL) is a promising biomarker of
neurodegeneration. Objectives To determine whether plasma and CSF NfL (1) associate …

In a range of neurological conditions, including movement disorders, sex-related differences
are emerging not only in brain anatomy and function, but also in pathogenesis, clinical …